Novo Nordisk A/S with ticker code (NVO) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 118.79 and 114.99 with the average target price sitting at 116.89. Now with the previous closing price of 109.37 this would indicate that there is a potential upside of 6.9%. The 50 day MA is 101.81 and the 200 day MA is 100.93. The market cap for the company is $248,942m. Company Website: https://www.novonordisk.com
The potential market cap would be $266,059m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
